Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

CCCC : 6.45 (+14.97%)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CCCC : 6.45 (+14.97%)
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

CCCC : 6.45 (+14.97%)
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

CCCC : 6.45 (+14.97%)
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults

/CNW/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale...

ONCY : 1.1400 (-3.39%)
TCRX : 5.08 (+2.63%)
BMY : 55.45 (+2.08%)
PDSB : 3.23 (+0.94%)
CCCC : 6.45 (+14.97%)
ONC.TO : 1.60 (-3.61%)
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates

USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around...

ONCY : 1.1400 (-3.39%)
ONC.TO : 1.60 (-3.61%)
TCRX : 5.08 (+2.63%)
BMY : 55.45 (+2.08%)
PDSB : 3.23 (+0.94%)
CCCC : 6.45 (+14.97%)
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial – – Phase 1/2 Clinical Trial for CFT8634, a...

CCCC : 6.45 (+14.97%)
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors

– Dr. Laura Bessen Brings More Than Two Decades of Experience Across Medical Affairs and Clinical Development in Support of Successful Product Launches – ...

CCCC : 6.45 (+14.97%)
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in...

CCCC : 6.45 (+14.97%)
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

– Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected...

CCCC : 6.45 (+14.97%)

Barchart Exclusives

What the Election Results May Mean for the Corn and Soybean Markets
Taking a look at whether the trade war comes back and what it means if it does. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar